Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead released Phase III data Feb. 4 strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.